New Pancreatic Cancer Drug Shows Striking Efficacy Against Top Mutation

REDWOOD CITY, CA – July 02, 2026 – In a significant development for one of oncology’s most challenging fields, Revolution Medicines today unveiled compelling clinical data for its targeted therapy, zoldonrasib, in patients with metastatic pancreatic cancer. The results, presented at the prestigious European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, demonstrate high response rates and manageable safety, positioning the drug to potentially become a cornerstone therapy for a large subset of patients with this devastating disease.

The Phase 1/2 trial data focuses on patients whose tumors harbor the RAS G12D mutation, the most common genetic driver in pancreatic ductal adenocarcinoma (PDAC), accounting for approximately 40% of cases. For decades, RAS mutations were considered “undruggable,” leaving patients with few options beyond grueling chemotherapy regimens that offer limited benefit. These new findings signal a potential paradigm shift, validating a novel scientific approach and providing a foundation for two pivotal Phase 3 trials that could bring the first targeted therapy to this specific patient population.

A New Front Against a Formidable Foe

Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate hovering just over 10%. Its aggressive biology and tendency for late-stage diagnosis mean that most patients face a grim prognosis. The standard of care has long been dominated by combination chemotherapy, but the search for more effective, targeted treatments has been relentless.

Revolution Medicines’ data offers a powerful glimmer of hope. In a cohort of previously untreated patients, combining zoldonrasib with the standard mFFX chemotherapy regimen produced an objective response rate (ORR) of 82%, meaning 82% of patients saw their tumors shrink significantly. The disease control rate (DCR), which includes patients whose tumors stopped growing, was an even more impressive 96%.

For patients who had already undergone prior treatment, a different combination showed remarkable promise. A chemotherapy-free doublet pairing zoldonrasib with daraxonrasib—the company's broader RAS inhibitor—yielded a 50% ORR and a 97% DCR in second-line patients. Critically, this group achieved a median progression-free survival (PFS) of 9.6 months, a substantial duration for this advanced stage of disease.

“The results presented at ESMO GI demonstrate compelling proof-of-concept for two zoldonrasib-based regimens in RAS G12D disease,” said Dr. Alan Sandler, chief development officer of Revolution Medicines. He noted that the findings provide the foundation for two distinct Phase 3 strategies the company is now pursuing in previously untreated patients, including the ongoing RASolute 305 trial and the planned RASolute 309 trial.

The Science of Targeting an 'Active' Enemy

What sets zoldonrasib and its sibling compound daraxonrasib apart is their mechanism of action. They are part of a class known as RAS(ON) inhibitors. The RAS protein acts like a molecular switch, cycling between an inactive 'OFF' state and an active 'ON' state that signals cells to grow and divide. In cancer, mutations lock this switch in the 'ON' position, driving relentless tumor growth.

While many early efforts focused on the inactive state, Revolution Medicines pioneered a strategy to directly target the active, cancer-driving RAS(ON) protein. Zoldonrasib is a highly selective oral inhibitor designed to form a “tri-complex” with the G12D-mutated RAS(ON) protein and another cellular protein, effectively shutting down its oncogenic signaling. This innovative approach is now bearing fruit, moving from a clever scientific concept to tangible clinical benefit.

Equally important for real-world application is the drug's safety profile. In the trials, the side effects of the zoldonrasib combinations were described as manageable and broadly consistent with what would be expected from the chemotherapy or daraxonrasib components alone. While Grade 3 or higher treatment-related adverse events were common, particularly in the chemotherapy arms, investigators reported that dose intensity remained high, suggesting patients were able to tolerate the treatment well enough to receive a therapeutic benefit. This balance of potent efficacy and manageable toxicity is the holy grail of drug development, especially in a fragile patient population.

A Crowded Field, A Clear Strategy

The race to drug RAS mutations is one of the most competitive and high-stakes arenas in modern oncology. Following the success of G12C inhibitors in lung cancer, numerous companies, including Mirati Therapeutics (now part of Bristol Myers Squibb), Astellas, and Incyte, are advancing their own G12D-targeted agents through the clinic. These programs employ diverse scientific strategies, from reversible inhibitors to targeted protein degraders (PROTACs).

Within this dynamic landscape, Revolution Medicines has carved out a formidable position with a multi-pronged strategy. The success of zoldonrasib, a G12D-selective agent, is complemented by the impressive data from daraxonrasib, a multi-selective inhibitor that targets a broader range of RAS mutations. In a separate Phase 3 trial reported earlier this year, daraxonrasib nearly doubled overall survival in previously treated pancreatic cancer patients, securing its status as a breakthrough therapy.

By advancing both a highly selective and a broad-spectrum RAS(ON) inhibitor, the company is building a franchise capable of addressing different patient segments and treatment settings. The plan to test a zoldonrasib-daraxonrasib doublet as a first-line therapy in the upcoming RASolute 309 trial is particularly ambitious, exploring a powerful, chemotherapy-free regimen that could redefine the standard of care if successful. The advancement of both combination strategies into global Phase 3 studies marks a critical transition from exploratory research to a clear path toward regulatory submission and commercialization.

From Bench to Bedside: The Path Forward

The clinical promise of zoldonrasib is amplified by shifts in clinical practice. The National Comprehensive Cancer Network (NCCN) now recommends comprehensive molecular profiling for all pancreatic cancer patients, a move designed to identify actionable mutations like RAS G12D. This ensures that as targeted drugs become available, the patients who can benefit from them are identified early.

Leading oncologists, speaking on background, have expressed strong optimism about the wave of new RAS inhibitors, calling it one of the most significant advances in the field in years. The consensus is that while monotherapies may provide a benefit, combination strategies like those being pursued by Revolution Medicines will likely be necessary to overcome tumor resistance and achieve durable responses. The 82% response rate seen with the zoldonrasib-chemotherapy combination is considered exceptional in first-line metastatic pancreatic cancer and sets a high bar for competitors.

With two pivotal Phase 3 trials now in motion, the oncology community will be eagerly watching to see if the remarkable promise shown in these early studies translates into extended survival for patients in larger, randomized trials. For the tens of thousands of people diagnosed each year with RAS G12D-driven pancreatic cancer, these results represent more than just industrial innovation; they represent a tangible source of new hope.